ProCE Banner Activity

CME

Key Questions on PARP Inhibitors in Ovarian Cancer: Experts Evaluate the Latest Evidence

Multimedia
Watch this on-demand webcast capturing a live CCO webinar to gain global perspectives on the latest data on safely and effectively leveraging PARP inhibitors for treating patients with ovarian cancer

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: July 20, 2021

Expiration: July 19, 2022

No longer available for credit.

Share

Faculty

Prof Jonathan A. Ledermann

Prof Jonathan A. Ledermann, MD, FRCP, FMed Sci

Professor of Medical Oncology
CRUK and UCL Cancer Trials Centre
UCL Cancer Institute
Honorary Consultant in Medical Oncology
Cancer Services
UCL Hospitals
London, United Kingdom

Frederik Marmé

Frederik Marmé, MD, PhD

Assistant Professor of Gynecology
Division of Gynecologic Oncology
Medical Faculty of Heidelberg
University of Heidelberg
Heidelberg, Germany

Prof Isabelle Ray-Coquard

Prof Isabelle Ray-Coquard, MD, PhD

President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Target Audience

This educational program is intended for global gynecologic oncologists, medical oncologists, and other healthcare professionals who care for patients with ovarian cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate available long-term follow-up data from clinical trials investigating the use of PARP inhibitors in the management of ovarian cancer
  • Apply new clinical findings in a clinical context and understand their therapeutic implications to optimize outcomes for patients with ovarian cancer
  • Identify patients with ovarian cancer most likely to benefit from PARP inhibitor therapy as single agents or in combination
  • Compare and contrast the toxicities associated with PARP inhibitors commonly used in therapy for ovarian cancer, and understand the available supportive management strategies
  • Discuss with patients and colleagues ongoing clinical studies of PARP inhibitor–based treatment in ovarian cancer

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Prof Jonathan A. Ledermann, MD, FRCP, FMed Sci

Professor of Medical Oncology
CRUK and UCL Cancer Trials Centre
UCL Cancer Institute
Honorary Consultant in Medical Oncology
Cancer Services
UCL Hospitals
London, United Kingdom

Prof Jonathan A. Ledermann, MD, FRCP, FMed Sci, has disclosed that he has received consulting fees from AstraZeneca, Clovis, Eisai, GlaxoSmithKline, MSD/Merck, Pfizer, and Regeneron.

Frederik Marmé, MD, PhD

Assistant Professor of Gynecology
Division of Gynecologic Oncology
Medical Faculty of Heidelberg
University of Heidelberg
Heidelberg, Germany

Frederik Marmé, MD, PhD, has disclosed that he has received consulting fees from Amgen, AstraZeneca, Celgene, Clovis, CureVac, Eisai, Genomic Health, Immunomedics, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Tesaro, and Vaccibody.

Prof Isabelle Ray-Coquard, MD, PhD

President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France

Prof Isabelle Ray Coquard has disclosed that she has received consulting fees from Amgen, AstraZeneca, Clovis, Deciphera, GlaxoSmithKline, Mersana, MSD, and Roche.

Staff Disclosure

Staff

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 20, 2021, through July 19, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to educate global gynecologic oncologists, medical oncologists, nurses, and other healthcare professionals about the recent developments in the use of PARP inhibitors in the treatment of ovarian cancer.